Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research

Criteria

Inclusion Criteria:

• Diagnosis of age-related macular degeneration in study eye, as specified in protocol.

• Poor visual acuity in study eye, as specified in protocol.

• Willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to study treatment.

• Females must be post-menopausal and/or surgically sterile.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Treatments to the study eye within 28 days prior to study treatment, as specified in protocol.

• Any disease or medication expected to cause systemic or ocular immunosuppression.

• Participation in another interventional clinical study or use of any experimental treatment for AMD within 12 weeks prior to study treatment.

• Other protocol-defined exclusion criteria may apply.